Conference Coverage

Dolutegravir-based regimen effective in HIV/TB coinfected

 

Key clinical point: Dolutegravir twice daily appears to be effective and safe in patients with HIV and TB who are on rifampin-based treatment.

Major finding: The virologic response rate at 24 weeks with dolutegravir was 81%.

Data source: Randomized noncomparative trial of 113 patients with HIV/TB coinfections in seven countries.

Disclosures: Dr. Dooley reported research support via her university from ViiV Healthcare, which funded the study.

Source: Dooley K et al. Abstract 33.


 

REPORTING FROM CROI

– In antiretroviral therapy–naive patients with HIV and tuberculosis coinfection, a combination of dolutegravir-based ART and rifampin-based TB therapy was associated with good efficacy and immunological responses through at least 24 weeks, investigators reported.

Dolutegravir-based ART appeared to be comparable to efavirenz-based therapy at viral suppression with a similar safety profile, although the trial was not powered for head-to-head comparison, said Kelly Dooley, MD, of Johns Hopkins University, Baltimore.

“We know that rifampin reduces concentrations of dolutegravir substantially, but that drug interaction can be mitigated by increasing the dose of dolutegravir to twice daily. That information was from a healthy volunteer trial, so we thought it would be important to test HIV/TB cotreatment among patients who have both infections,” she said at the Conference on Retroviruses and Opportunistic Infections.

Dr. Dooley and her colleagues looked at dolutegravir or efavirenz plus rifampin-based TB therapy in the INSPIRING trial.

Next Article: